Search Results

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Molecular Targeting Technologies, Inc., is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel.

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

Molecular Targeting Technologies, Inc., and its wholly owned subsidiary, Molecular Theranostic Center of Singapore, announced the approval of a Clinical Trial Authorization application by the Health Sciences Authority of Singapore.

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.

Degron Therapeutics, the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, announced it has entered into a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.